Amylyx Pharmaceuticals (AMLX) vs Parabilis Medicines (PBLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Parabilis Medicines is the larger company by market cap ($3.47 billion vs $3.41 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | PBLS |
|---|---|---|
| Share price | $27.20 | $28.09 |
| Market cap | $3.41B | $3.47B |
| 1-day change | -0.84% | -2.53% |
| YTD return | +125.17% | — |
| 1-year return | +101.78% | — |
| EPS (TTM) | $-1.41 | $-9.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-144.74M | — |
| 52-week high | $41.14 | $42.49 |
| 52-week low | $10.83 | $24.51 |
| Distance from 52-week high | -33.88% | -33.89% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +55.74% | +48.63% |
| Average volume | 2.35M | 690.91K |
| Shares outstanding | 125.51M | 121.95M |
| Employees | 136 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
AMLX vs PBLS FAQ
Which is bigger, Amylyx Pharmaceuticals or Parabilis Medicines?
Parabilis Medicines (PBLS) is larger, with a market capitalization of $3.47B compared with $3.41B for Amylyx Pharmaceuticals (AMLX).
Are Amylyx Pharmaceuticals and Parabilis Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.